Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study - Takeaways - MDSpire

Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study

  • By

  • Fumiyuki Goto

  • Koichiro Wasano

  • June 3, 2026

  • 0 min

Share

  • 1

    Aripiprazole was evaluated as a second-line treatment for patients with refractory functional dizziness disorders, including PPPD.

  • 2

    In a retrospective analysis of 16 patients, 75% showed improvement in symptoms after treatment with aripiprazole.

  • 3

    The study included patients with various dizziness disorders, with PPPD being the most common diagnosis among participants.

  • 4

    Adverse effects led to one patient discontinuing aripiprazole, while others reported improvements in Dizziness Handicap Inventory and Niigata PPPD Questionnaire scores.

  • 5

    The findings suggest aripiprazole may effectively target symptoms inadequately managed by first-line serotonergic agents, warranting further research.

Original Source(s)

Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study

  • by Fumiyuki Goto, Koichiro Wasano

  • June 3, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

Objective oculomotor, vestibular, reaction time, and cognitive signatures of vestibular migraine